Korsuva (difelikefalin)
Chronic Kidney Disease-Associated Pruritus (CKD-aP)
MarketedStrategic Review
Key Facts
Indication
Chronic Kidney Disease-Associated Pruritus (CKD-aP)
Phase
Marketed
Status
Strategic Review
Company
About Tvardi Therapeutics
Tvardi Therapeutics is a Houston-based biotech focused on developing oral STAT3 inhibitors to treat fibrosis-driven, inflammatory, and proliferative diseases. Founded in 2017, the company has progressed its lead asset, TTI-101, into Phase 2 trials for IPF and liver cancer. Its strategy leverages a novel, direct STAT3 inhibition platform with broad therapeutic potential, recently bolstered by a 2025 merger with Cara Therapeutics to enhance resources and pipeline depth.
View full company profile